
Current Price | $0.54 | Mkt Cap | $9.2M |
---|---|---|---|
Open | $0.53 | P/E Ratio | -0.41 |
Prev. Close | $0.54 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.50 - $0.54 | Volume | 41,584 |
52-Wk Range | $0.39 - $1.26 | Avg. Daily Vol. | 119,987 |
A development-stage, specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases.
Current Price | $0.54 | Mkt Cap | $9.2M |
---|---|---|---|
Open | $0.53 | P/E Ratio | -0.41 |
Prev. Close | $0.54 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.50 - $0.54 | Volume | 41,584 |
52-Wk Range | $0.39 - $1.26 | Avg. Daily Vol. | 119,987 |
The best Bull and Bear pitches based on recency and number of recommendations.
Synthetic Biologics seems to be back in fashion among the momentum crowd, but the company will always be a name-changing, shape-shifting, perma-disappointer to me. Traders are looking ahead to topline data from the phase II trial of SYN-010 in IBS-C,… More
Read the most recent pitches from players about SYN.
Recs
This is a reup of a former Red thumb.
-----
Crap pharma. Has not been profitable in 10 years.
Recs
Trimesta results in April will double stock value.
Recs
I have to respectfully disagree with zz below. Zinth is definitely not a cure for Alzheimer's, and it is not advertised as such. It is a prescription medical food meant to slow cognitive degradation seen in Alzheimer's and similar diseases. The hypothesis is that since there is a significant correlation between zinc deficiency and degradation of cognitive function, taking zinc supplements may slow cognitive deterioration. Zinth is comprised of zinc and cysteine, and both components are generally regarded as safe, which reduces the number of hurdles Adeona has to overcome to get it to market. Zinth's differentiation from standard zinc supplements is its ease of digestion, whereas common zinc supplements commonly have side effects of indigestion, nausea, and heartburn. Anecdotal results have been positive so far:
http://www.crainsdetroit.com/article/20110102/SUB01/301029993/alzheimers-trial-may-win-deal-for-adeona-supplement-interests-drug-firms#
Beyond Zinth, they are also in various stages of testing 4 other drugs for drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis, a couple of which have blockbuster potential. The management team, led by Dr. Kuo, is stellar, and insiders own 47% of the company. Recently, they added Dr. Anand Prasad to the team, a pioneer in zinc research.
Adeona has already received term sheets for Zinth from potential pharma partners, but nothing has been announced yet. The final data from the Zinc trials will be announced in March, although a partnership may come before then. Kuo has announced that Adeona will hold an investor day on February 8th, during which he will discuss plans for Zinth. If a partnership deal has been signed, that would probably be the day he announced it...
Find the members with the highest scoring picks in SYN.
Seal07 (< 20) Score: +357.76
The Score Leader is the player with the highest score across all their picks in SYN.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
Seal07 | < 20 | 8/15/2011 |
![]() |
1Y | $280.18 | -99.82% | +257.94% | +357.76 | 0 Comment | |
Bill292 | 28.03 | 1/3/2012 |
![]() |
5Y | $437.50 | -99.88% | +233.53% | +333.41 | 0 Comment | |
mainakn | < 20 | 3/22/2011 |
![]() |
3M | $609.00 | -99.92% | +229.95% | +329.86 | 0 Comment | |
EvilEmpire | 26.18 | 1/12/2012 |
![]() |
5Y | $595.00 | -99.91% | +229.92% | +329.84 | 0 Comment | |
SpecEdSquadron | 90.82 | 4/17/2012 |
![]() |
NS | $602.00 | -99.91% | +210.13% | +310.04 | 0 Comment | |
pear4000 | 27.26 | 8/15/2012 |
![]() |
3M | $713.65 | -99.93% | +203.03% | +302.95 | 0 Comment | |
cfayles | 29.22 | 10/25/2007 |
![]() |
5Y | $2,362.50 | -99.98% | +197.03% | +297.01 | 0 Comment | |
SissorsC | 66.00 | 10/5/2007 |
![]() |
3Y | $2,362.50 | -99.98% | +188.90% | +288.88 | 0 Comment | |
FesterFumble | 50.84 | 4/28/2014 |
![]() |
5Y | $1,011.50 | -99.95% | +128.54% | +228.49 | 0 Comment | |
TimeToBuy | 91.87 | 1/7/2015 |
![]() |
5Y | $560.00 | -99.91% | +112.23% | +212.14 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.